UNDERWRITING AGREEMENT between CYTOMED THERAPEUTICS LIMITED and THE BENCHMARK COMPANY, LLC as Representative of the Several Underwriters CYTOMED THERAPEUTICS LIMITEDUnderwriting Agreement • April 18th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations • New York
The undersigned, CytoMed Therapeutics Limited, a public company limited by shares pursuant to the provisions of the Singapore Companies Act formed under the laws of the Republic of Singapore (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or affiliates of CytoMed Therapeutics Limited, the “Company”), hereby confirms its agreement (this “Agreement”) with The Benchmark Company, LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
Form of Representative’s Warrant AgreementRepresentative’s Warrant Agreement • April 18th, 2023 • CytoMed Therapeutics LTD • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 2023 (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (New York time) on the date that is five (5) years following the commencement date of sales in the Offering (the “Termination Date”) but not thereafter, to subscribe for and purchase from CytoMed Therapeutics Limited, a public company limited by shares pursuant to the provisions of the Singapore Companies Act formed under the laws of the Republic of Singapore (the “Company”), up to ______ Ordinary Shares, no par value per share, of the Company (the “Warrant Shares”), as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defi
